newsfilter
← Latest News
PR Newswire·

Sobi to cease ReFacto manufacturing in the first quarter of 2024

STOCKHOLM, March 23, 2022 /PRNewswire/ -- Sobi® today announced that its contract with Pfizer for the manufacture of drug substance for ReFacto AF®/Xyntha® (ReFacto) has been amended due to clarity of final order volumes and will now expire in the fir